Drug Profile
ALLN 346
Alternative Names: ALLN-346; Engineered urate oxidaseLatest Information Update: 05 Jul 2023
Price :
$50
*
At a glance
- Originator Allena Pharmaceuticals
- Class Antigouts; Enzymes; Oxidoreductases; Uricosurics; Urologics
- Mechanism of Action Urate oxidase replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Gout; Hyperuricaemia; Renal failure
Most Recent Events
- 23 Jun 2023 Allena Pharmaceuticals terminates a phase II clinical trials in Renal failure (In adults, In the elderly) due to company financing in USA (PO) (NCT04987294)
- 01 Jun 2022 Pharmacokinetics, efficacy and adverse events data from a phase IIa trial in Hyperuricaemia presented at the 23rd Annual Congress of the European League Against Rheumatism (EULAR-2022)
- 01 Jun 2022 Pooled pharmacokinetics and adverse events data from two phase I trials in Hyperuricaemia presented at the 23rd Annual Congress of the European League Against Rheumatism (EULAR-2022)